“White blood cell counts can predict whether or not lung cancer patients will benefit from immunotherapy, according to research presented at the European Lung Cancer Conference (ELCC).
” ‘Immune checkpoint inhibitors such as nivolumab and pembrolizumab significantly improve overall survival in some – but not all – patients with non-small cell lung cancer (NSCLC),’ said lead author Dr Marcello Tiseo, Coordinator of DMT Thoracic Oncology, University Hospital of Parma, Italy. ‘Researchers are looking for a predictive biomarker to select patients that will benefit from this treatment to avoid unnecessary toxicity and a waste of resources in patients who will not respond.’ ”
A type of white blood cell can infiltrate and attack tumors, and researchers have just launched a clinical trial of an experimental immunotherapy designed to sharpen this attack against melanoma. These white blood cells are called killer T cells, and the first step is collecting them from people with melanomas that have spread. Then two genes are inserted into the killer T cells to make them seek tumor cells. Next, the people are treated with chemotherapy to wipe out their remaining T cells, which do not recognize tumor cells as abnormal. The final step is treating people with their own genetically-modified killer T cells in hopes that these will then attack tumors. This phase I trial is currently recruiting participants.